


Endocan / ESM-1

Biomarker of intratumoral
endothelium in lung cancers

Monoclonal antibody MEP08



The monoclonal antibody against human endocan / ESM-1 called MEP08¹ (LIA-0901) is a pertinent biomarker to evaluate endothelial activation and neoangiogenesis in lung cancers


Background

Endocan also called endothelial cell specific molecule 1 (ESM-1) is a pertinent **biomarker of endothelial dysfunction** (Sarrazin et al. 2010). In lung cancer, endocan / ESM-1 is detected by immunochemistry in small and large intratumoral vessels (Grigoriu et al. 2006). In vitro, Endocan / ESM-1 is upregulated in presence of pro-angiogenic molecules such as VEGF (Sarrazin et al. 2010). Recently, endocan was shown to be overexpressed in **tip cells** during **neoangiogenesis** (Strasser et al. 2010 ; Recchia et al. 2010).

Blood levels of endocan has been shown to be increased in patients with **poor prognosis** in lung cancers (Scherpereel et al. 2003 ; Grigoriu et al. 2006). Interestingly, VEGF-induced endocan secretion was shown to be fully abolished in presence of anti-angiogenic drugs (Grigoriu et al. 2006 ; Leroy et al. 2010).

References

Grigoriu et al. (2006) Clin. Cancer Res. 12:4575-4582
Leroy et al. (2010) Histopathology 56:180-187
Recchia et al. (2010) Invest. Ophthalmol. Vis. Sci. 2:1098-1105
Sarrazin et al. (2010) J. Cancer. Sci. Ther. 2:47-52
Scherpereel at al. (2003) Cancer Res. 63:6084-6089
Strasser et al. (2010) Blood 115:5102-5110



Survival curves according blood levels of endocan / ESM-1 as quantified by ELISA (DIYEK EndoMark H1, Ref. LIK-1101) in patients suffering from lung cancers (according Grigoriu et al. 2006).

Main features

- Monoclonal antibody (mouse)
- Easy to use / do not required any enzymatic pre-treatment
- Recommended for immunohistochemistry (paraffin and frozen sections)
- Can be use with automatized procedures
- Specific of the N-terminus of human endocan
- Stored at 4°C / -20°C

¹ This product is for research use only and is not intended for diagnostic or therapeutic use

Lunginnov
Campus de l'Institut Pasteur de Lille
1 rue du Pr Calmette, 59000 LILLE, France
Tel : (33) 320 877 211 / Fax : (33) 320 877 884
E mail : contact@lunginnov.com
www.lunginnov.com

